Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2004

View Archived Issues

New class of antiinflammatory agents by Wyeth

Potent peripherally restricted mu agonist for pain therapy

Studies suggest that botulinum A toxin is both effective and safe in bladder disorders

Studies reveal tolerability and efficacy of darifenacin in overactive bladder

Urgency reduced by solifenacin in overactive bladder patients

New data on tamsulosin presented at the 19th EAU congress

RO-3202904 may be better tolerated than other overactive bladder treatments

Studies find dutasteride effective in benign prostatic hyperplasia

Atrasentan delays disease progression in metastatic prostate cancer

Strontium-89, olpadronate reduce bone pain in metastatic prostate cancer

NAD-299, RS-23597 active in prostate cancer cells

NIAID to support development of Crucell's candidate malaria vaccine

Innogenetics acquires Genencor's therapeutic vaccine programs

Vernalis to reacquire North American rights to frovatriptan

Amgen to acquire Tularik

YM BioSciences to commence pivotal tesmilifene trial in coming weeks

QLT acquiring Kinetek

Second phase III study of RSD-1235 in atrial fibrillation commences

Quigley completes pre-IND meeting for QR-333

Phase II Psoraxine trial under way

Enrollment opens in phase III trial of STR in multiple myeloma

Exenatide LAR enters phase II study in patients with type 2 diabetes

Amylin PYY obesity drug candidate enters phase I safety study

Enrollment completed in phase II obesity study of AC-137

CV Therapeutics seeks European approval of ranolazine for chronic angina

Remune selected for new Canadian HIV trial

Enrollment completed in phase II study of Deltavasc for PAD

Corporate developments at Merck & Co.

Second phase III study for Oxytrex

Corixa licenses RC-529 adjuvant rights to Aventis

PARP inhibitors claimed in Kyorin patents

Takeda discloses novel series of beta-secretase inhibitors

Inhibitors of sodium-dependent glucose co-transporter emerge from Taisho research

Compounds for treatment of pneumovirus infections covered in ViroPharma patent

Bayer claims diagnostics and therapeutics for GPR19-associated diseases

Resorcinol derivatives for the treatment of diabetes claimed by Sankyo

Procter & Gamble patent covers new antimicrobial quinolones

Pladienolide D derivative, E-7107, shows good antitumor activity in xenografts

Promising MIF inhibitor for prophylaxis and treatment of type 1 diabetes

Congress presentations report PD-0332991's biochemical, pharmacological and pharmacokinetic profile

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...